MPNs

Latest News

Latest Videos

Identifying a Diagnosis of Myelofibrosis

Presentation and Risk Stratification of Myelofibrosis

Case Presentation: Primary Myelofibrosis

The Clinical Management of Primary Myelofibrosis

Myelofibrosis-Associated Complications and Future Therapies

Myelofibrosis: Long-Term Survival Data and Ruxolitinib Use

Myelofibrosis: Goals of Therapy and Survival Outcomes

Initial Impression and Presentation of Myelofibrosis

Diagnosis and Treatment of Myelofibrosis

Ruxolitinib as Second-Line Therapy in Polycythemia Vera

CME Content

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Kamel Abou Hussein, MD; Yan Ji, MD, PhD

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Virginia Kaklamani, MD, DSc; Denise Yardley, MD, GCRA

Virtual Event

North Carolina Oncology Association

1 Sessions is Available!

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Kamel Abou Hussein, MD; Kit Y Lu, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Kamel Abou Hussein, MD; Kimberly Ku, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Sara A. Hurvitz, MD, FACP; Milana Dolezal, MD, MSci

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Nevada Oncology Society

Sara A. Hurvitz, MD, FACP; Ajit K. Bisen, MD, MBA

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Empire State Hematology & Oncology Society

Wassim Mchayleh, MD, MBA, FACP; Yelda Nouri, MD

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | West Virginia

Neil M. Iyengar, MD; Swati Vishwanathan, MD

Virtual Event

Missouri Oncology Society

1 Session is Available!

Virtual Event

New Mexico Society of Clinical Oncology

3 Sessions are Available!

Virtual Event

Nevada Oncology Society

2 Sessions are Available!

Virtual Event

Louisiana Oncology Society

2 Sessions are Available!

Virtual Event

Montana State Oncology Society

1 Session is Available!

In-Person Event

24th Annual School of Breast Oncology

November 5-7, 2026

Virtual Event

Rhode Island Oncology Society

1 Session is Available!

Video

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Video

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Video

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Video

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Video

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Video

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Video

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Video

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Video

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Video

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Video

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Video

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

Video

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD

Video

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

Video

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; Sara Nunnery, MD, MSCI

Video

Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer

Joyce O’Shaughnessy, MD; Reshma L. Mahtani, DO; Heather McArthur, MD, MPH; Paolo Tarantino, MD, PhD

Video

Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging Therapies

Adam Brufsky, MD, PhD; Kamel Abou Hussein, MD; Priyanka Sharma, MD, FASCO

More News

Examining the Link Between High-Risk Mutations and Transplant Outcomes in Myelofibrosis

ByDanielle Ternyila

May 23rd 2019

Raajit K. Rampal, MD, PhD, discusses a retrospective analysis of pre-transplant samples from patients with MF to determine the value of mutational profiling in predicting outcomes after transplant.

Glasdegib Safety, Tolerability Deemed Manageable in Pretreated Myelofibrosis But Trial Halted Due to Missed Endpoints

ByDarcy Lewis

May 21st 2019

A new report published in<em> Leukemia Research</em> found that results from the lead-in cohort of an open-label phase lb/II trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with at least 1 JAK inhibitor indicated acceptable safety and tolerability.

MPNs

Latest News

Latest Videos

Identifying a Diagnosis of Myelofibrosis

Presentation and Risk Stratification of Myelofibrosis

Case Presentation: Primary Myelofibrosis

The Clinical Management of Primary Myelofibrosis

Myelofibrosis-Associated Complications and Future Therapies

Myelofibrosis: Long-Term Survival Data and Ruxolitinib Use

Myelofibrosis: Goals of Therapy and Survival Outcomes

Initial Impression and Presentation of Myelofibrosis

Diagnosis and Treatment of Myelofibrosis

Ruxolitinib as Second-Line Therapy in Polycythemia Vera

CME Content

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

North Carolina Oncology Association

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | West Virginia

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Nevada Oncology Society

Louisiana Oncology Society

Montana State Oncology Society

24th Annual School of Breast Oncology

Rhode Island Oncology Society

9th Annual School of Nursing Oncology™

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer

Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging Therapies

More News

Examining the Link Between High-Risk Mutations and Transplant Outcomes in Myelofibrosis

Glasdegib Safety, Tolerability Deemed Manageable in Pretreated Myelofibrosis But Trial Halted Due to Missed Endpoints

The Future of Polycythemia Vera Treatment

Ruxolitinib: Adverse Events & First-Line Plausibility

The Role of Ruxolitinib in Treating Polycythemia Vera

Rationale for Switching Polycythemia Therapy

Thrombosis, Myelofibrosis, and Acute Myeloid Leukemia

Polycythemia Vera: Treatment Goals & Risk Stratification

Diagnosing Polycythemia Vera

Case Overview: A 58-Year-Old Woman With Polycythemia Vera

A 58-Year-Old Woman with Polycythemia Vera

Stepping Forward: Future Treatment of Myelofibrosis

Treating With a JAK Inhibitor for Myelofibrosis

Treatment Options for a Patient With Myelofibrosis

Prognostic Classification Systems in Myelofibrosis

Criteria Used in the Diagnosis of Myelofibrosis

JAK Inhibition for the Management of Primary Myelofibrosis

Addressing Unmet Needs in the Management of Myelofibrosis

Ruxolitinib Therapy for Patients With Myelofibrosis

The COMFORT-I and COMFORT-II Trials in Myelofibrosis

Treatment Considerations in Myelofibrosis

Risk Stratification for Patients With Myelofibrosis

Considerations in the Assessment of Myelofibrosis

Primary Myelofibrosis

Treating PV With JAK Inhibition Now and in the Future

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment

What to Watch at IMS 2026: Defining Cure as Multitargeting, CELMoDs, and In Vivo CAR T Move Forward

Tovecimig Submission for Biliary Tract Cancer Is Proceeding Despite FDA Request for New Trial

Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera

177Lu-Dotatate Radioequivalent Earns Final FDA Approval in GEP-NETs